Evidence map›Paper›PMID 28785925›Full record

ReviewDer Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete2017

[Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma].

R Stranzenbach, S Theurich, M Schlaak

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

R StranzenbachUniversitätsklinik für Dermatologie, Venerologie, Allergologie und Phlebologie, Johannes Wesling Klinikum Minden, Universitätsklinikum der Ruhr-Universität Bochum, Hans-Nolte-Str. 1, 32429, Minden, Deutschland. rene.stranzenbach@rub.de.
S TheurichKlinik I für Innere Medizin, Stammzelltransplantationsprogramm, Centrum für Integrierte Onkologie (CIO) Köln-Bonn, Universitätsklinikum Köln, Köln, Deutschland.
M SchlaakKlinik für Dermatologie und Venerologie, Hauttumorzentrum CIO Köln-Bonn, Universitätsklinikum Köln, Köln, Deutschland.
Centrum für Integrierte Onkologie · DEJohannes Wesling Klinikum Minden · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWithin the heterogeneous group of cutaneous T‑cell lymphomas (CTCL) the therapeutic options for advanced and progressive forms are particularly limited.

objectiveThe therapeutic value of hematopoietic stem cell transplantation in CTCL was analyzed. MATERIAL AND

methodsA literature search using the keywords "hematopoietic stem cell transplantation" and "cutaneous T‑cell lymphoma" was performed in PubMed. Studies between 1990 and 2017 were taken into account. The studies identified were analyzed for relevance and being up to date.

resultsAfter reviewing the currently available literature no prospective randomized studies were found. Wu et al. showed a superiority of allogeneic transplantation in a comparison of autologous and allogeneic stem cell transplantation for cutaneous lymphoma. The graft-versus-lymphoma effect plays a significant role in a prolonged progression-free survival after allogeneic transplantation. By using a non-myeloablative conditioning regimen, stem cell transplantation can also be an option for elderly patients. The most extensive long-term data after allogeneic stem cell transplantation were reported by Duarte et al. in 2014.

conclusionAutologous stem cell transplantation does not currently represent a therapeutic option, whereas allogeneic stem cell transplantation for advanced cutaneous T‑cell lymphoma, using a non-myeloablative conditioning scheme, does represent a therapeutic option. However, there is no consensus on the appropriate patients and the right timing. Morbidity and mortality of complications should be taken into account. Thus, this procedure is currently subject to an individual case decision.

Indexed as

Hematopoietic Stem Cell TransplantationAgedAllograftsAutograftsDisease ProgressionHumansLymphoma, T-Cell, CutaneousMiddle AgedNeoplasm StagingProgression-Free SurvivalSkin NeoplasmsAllogeneicAutologousComorbiditiesHematopoietic stem cell transplantationProgression

Identifiers

PMID28785925
OpenAlexW2745132301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.